Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday. The company provided earnings per share guidance of $6.60-6.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.03
Alexion Pharmaceuticals (NASDAQ:ALXN) updated its FY18 earnings guidance on Thursday. The company provided earnings per share guidance of $6.60-6.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.03. The company issued revenue guidance of $3.85-3.95 billion, compared to the consensus revenue estimate of $4.06 billion.
A number of equities research analysts recently issued reports on the stock. ValuEngine cut shares of Alexion Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday. Deutsche Bank set a $161.00 price target on shares of Alexion Pharmaceuticals and gave the company a buy rating in a research note on Friday, February 9th. BMO Capital Markets lifted their price target on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an outperform rating in a research note on Friday, February 9th.
Citigroup dropped their price target on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a buy rating on the stock in a research note on Friday, February 9th. Finally, Stifel Nicolaus reissued a buy rating and issued a $151.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $152.77.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $2.81 during mid-day trading on Friday, hitting $117.92. 1,340,000 shares of the stock traded hands, compared to its average volume of 2,050,000. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. The firm has a market cap of $26,140.00, a PE ratio of 54.34, a price-to-earnings-growth ratio of 1.09 and a beta of 1.13. Alexion Pharmaceuticals has a 1 year low of $96.18 and a 1 year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 EPS. analysts expect that Alexion Pharmaceuticals will post 6.12 EPS for the current fiscal year.
In other news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30.
Following the transaction, the senior vice president now directly owns 32,635 shares in the company, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,253 shares of company stock worth $3,656,229. Corporate insiders own 4.35% of the company’s stock.
